PRC-063 oral capsules — Competitive Intelligence Brief

PRC-063 oral capsules (PRC-063 oral capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Pain, Depression.

phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Pain, Depression Small molecule

Target snapshot

PRC-063 oral capsules (PRC-063 oral capsules) — Purdue Pharma, Canada. PRC-063 oral capsules are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PRC-063 oral capsules TARGET	PRC-063 oral capsules	Purdue Pharma, Canada	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)
Pristiq	Desvenlafaxine Succinate	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine reuptake	2008-01-01
Effexor	Venlafaxine Hydrochloride	Pfizer	marketed	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)	Serotonin and norepinephrine reuptake transporters	1993-01-01
desvenlafaxine succinate sustained release	desvenlafaxine succinate sustained release	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Venlafaxine XR	Venlafaxine XR	Ministry of Health & Welfare, Korea	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
Venlafaxine IR and Venlafaxine XR	Venlafaxine IR and Venlafaxine XR	North Dakota State University	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Treatment (Viibryd)	Treatment (Viibryd)	Southern California Institute for Research and Education	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity	Serotonin transporter (SERT); 5-HT1A receptor (partial agonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

1. Pfizer · 3 drugs in this class
2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
3. National Institute of Mental Health (NIMH) · 2 drugs in this class
4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
5. Eli Lilly and Company · 2 drugs in this class
6. New York State Psychiatric Institute · 1 drug in this class
7. North Dakota State University · 1 drug in this class
8. Ministry of Health & Welfare, Korea · 1 drug in this class
9. Purdue Pharma, Canada · 1 drug in this class
10. Shanghai Mental Health Center · 1 drug in this class